Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Rafael Holdings, Inc. (RFL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RFL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -53.72% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 58.96M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 29451 | Beta 1.15 | 52 Weeks Range 1.29 - 2.50 | Updated Date 04/1/2025 |
52 Weeks Range 1.29 - 2.50 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-11 | When Before Market | Estimate - | Actual -0.1922 |
Profitability
Profit Margin - | Operating Margin (TTM) -4661.04% |
Management Effectiveness
Return on Assets (TTM) -47.85% | Return on Equity (TTM) -93.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3091500 | Price to Sales(TTM) 86.24 |
Enterprise Value 3091500 | Price to Sales(TTM) 86.24 | ||
Enterprise Value to Revenue 21.18 | Enterprise Value to EBITDA 5.39 | Shares Outstanding 31257800 | Shares Floating 19206502 |
Shares Outstanding 31257800 | Shares Floating 19206502 | ||
Percent Insiders 16.1 | Percent Institutions 7.66 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rafael Holdings, Inc.
Company Overview
History and Background
Rafael Holdings, Inc., founded in 2017, is a pharmaceutical company focused on developing and commercializing therapies in oncology and immune-related diseases. It evolved from a real estate investment company to a biopharmaceutical entity.
Core Business Areas
- Oncology: Development of therapies for cancer, particularly targeting altered metabolism pathways in cancer cells.
- Early Access Program (EAP): Facilitates investigational drug availability before commercialization for patients with urgent medical needs.
Leadership and Structure
The leadership team includes Ameet Mallik (CEO). The organizational structure is typical of a biopharmaceutical company, encompassing R&D, clinical development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- Devimistat: An investigational drug targeting cancer cell metabolism. It is in clinical trials for various cancers. Market share is currently 0% as it is not yet approved. Key competitors in relevant cancer treatment areas are companies like Bristol Myers Squibb (BMY), Merck (MRK), and Roche (ROG) who have marketed products to treat cancer.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive, marked by strict regulatory approvals, patent protection, and substantial investment in R&D.
Positioning
Rafael Holdings is a smaller player focused on niche oncology targets, relying heavily on clinical trial success and potential partnerships. Competitive advantages lie in its unique metabolic-targeting approach.
Total Addressable Market (TAM)
The global oncology market is estimated to be in hundreds of billions of dollars. Rafael Holdings, if successful, could capture a small portion of this market with Devimistat. The TAM related to its particular metabolic niche is smaller, but still substantial.
Upturn SWOT Analysis
Strengths
- Novel approach to cancer treatment (metabolic targeting)
- Experienced management team
- Focused pipeline
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Small company size
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into other disease areas
- Positive clinical trial results leading to FDA approval
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
- AMGN
- GILD
Competitive Landscape
Rafael Holdings faces intense competition from larger, established pharmaceutical companies with greater resources and broader pipelines. Its advantage lies in its unique therapeutic approach.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal as the company is pre-revenue. Growth is expected to occur upon successful commercialization of a product.
Future Projections: Future growth is highly uncertain and dependent on regulatory approval and market acceptance of Devimistat. Analyst estimates vary widely.
Recent Initiatives: Focus on advancing Devimistat through clinical trials, seeking partnerships, and exploring new indications.
Summary
Rafael Holdings is a high-risk, high-reward pharmaceutical company focused on a novel cancer treatment approach. Its success hinges on the positive outcomes of its clinical trials and regulatory approvals. While it has a focused pipeline, it faces intense competition and requires significant funding to continue its research. Investors should carefully consider the risks before investing.
Similar Companies
ARRY
Array Technologies Inc
ARRY
Array Technologies Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Corporate Website
- Analyst Reports
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rafael Holdings, Inc.
Exchange NYSE | Headquaters Newark, NJ, United States | ||
IPO Launch date 2018-03-26 | CEO & President Mr. William Conkling | ||
Sector Real Estate | Industry Real Estate Services | Full time employees 28 | Website https://www.rafaelholdings.com |
Full time employees 28 | Website https://www.rafaelholdings.com | ||
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylated catalytic intermediates of lipoate currently under phase 2 open-label multi-cohort study evaluating CPI-613 in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemorefractory colorectal, pancreatic, or other solid cancers; and under phase 1 dose-escalation study of CPI-613 in combination with chemoradiation in patients with pancreatic adenocarcinoma. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.